Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related chronic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and requires minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Location: Sweden, Gothenburg
Employees: 1-10
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Almi Inves... | almi.se |
| - | Chalmers V... | chalmersve... |
Mentions in press and media 20
| Date | Title | Description |
| 20.08.2025 | (SV) Stayble Therapeutics offentliggör halvårsrapport för 2025 | (SV) Stayble Therapeutics offentliggör halvårsrapport för 2025 Wed, Aug 20, 2025 09:00 CET Report this content Stayble Therapeutics AB ("Stayble" eller "Bolaget") offentliggör härmed halvårsrapport för 2025. Rapporten fi... |
| 21.05.2025 | (SV) Stayble Therapeutics offentliggör kvartalsrapport för första kvartalet 2025 | (SV) Stayble Therapeutics offentliggör kvartalsrapport för första kvartalet 2025 Wed, May 21, 2025 08:30 CET Report this content Stayble Therapeutics AB ("Stayble" eller "Bolaget") offentliggör härmed kvartalsrapport för... |
| 14.05.2025 | (SV) Stayble Therapeutics publicerar årsredovisningen för 2024 | (SV) Stayble Therapeutics publicerar årsredovisningen för 2024 Wed, May 14, 2025 12:30 CET Report this content Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2024. Årsredovisningen finns tillgänglig... |
| 07.05.2025 | Byggmax and Stayble Therapeutics: A Tale of Two Annual General Meetings | On May 6, 2025, two companies held their Annual General Meetings (AGMs) in Sweden, each with its own unique narrative. Byggmax Group AB and Stayble Therapeutics AB showcased contrasting paths in the corporate landscape. One focused on solid... |
| 07.05.2025 | Navigating the Waters of Corporate Governance: Insights from Recent Shareholder Meetings | In the world of corporate governance, shareholder meetings are the compass guiding companies through turbulent waters. They are the moments when stakeholders gather to steer the ship, make decisions, and chart the course for the future. Rec... |
| 06.05.2025 | (SV) Kallelse till årsstämma i Stayble Therapeutics AB (publ) | (SV) Kallelse till årsstämma i Stayble Therapeutics AB (publ) Tue, May 06, 2025 13:38 CET Report this content Aktieägarna i Stayble Therapeutics AB (publ), org.nr 559024-8372, kallas till årsstämma den 5 juni 2025 kl. 13.00 på bolagets kont... |
| 25.02.2025 | Stayble Therapeutics publishes year-end report for 2024 | Stayble Therapeutics publishes year-end report for 2024 Tue, Feb 25, 2025 08:35 CET Report this content Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2024. The report is available as an attach... |
| 14.01.2025 | Interview with US payer expert on the US market and STA363´s potential | Interview with US payer expert on the US market and STA363´s potential Tue, Jan 14, 2025 08:00 CET Report this content Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Rachelle, a US Payer Expert abou... |
| 29.11.2024 | Stayble Therapeutics publishes interim report for the third quarter of 2024 | Stayble Therapeutics publishes interim report for the third quarter of 2024 Fri, Nov 29, 2024 08:30 CET Report this content Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the third quarter of 20... |
| 21.05.2024 | Stayble Therapeutics publishes interim report for the first quarter of 2024 | Stayble Therapeutics publishes interim report for the first quarter of 2024 Tue, May 21, 2024 08:30 CET Report this content Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the first quarter of 20... |
Show more